ACR Convergence 2023

November 10-15, 2023. San Diego, CA.

View by Number View by Title View Sessions

Abstract Number: 1494

The Effect of Belimumab on Steroid Use in Patients with SLE: Results from a Retrospective Observational Study of Real-World Data from a US Rheumatology Provider Network
Abstract Number: 1495

Deep Serological Profiling of SLE Patients Treated with anti-CD19 CAR T Cells
Abstract Number: 1496

Clinical Safety and Efficacy Results from EQUALISE Type B: A Phase 1b Open-label Clinical Study of Itolizumab, a Novel anti-CD6 Therapy, in Subjects with Active Proliferative Lupus Nephritis
Abstract Number: 1497

Eltrombopag in SLE-Associated Thrombocytopenia: Treatment Response and Thrombotic Complications
Abstract Number: 1498

First-in-Human Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Study of DS-7011a, an Anti-TLR7 Antagonistic Monoclonal Antibody for the Treatment of Systemic Lupus Erythematosus
Abstract Number: 1499

Year-5 Follow-up of Belimumab Safety (mortality and Malignancies) in Patients with Systemic Lupus Erythematosus (SLE) Who Completed a Phase 4, 52-week, Randomized, Double-blind Placebo-controlled Safety Study
Abstract Number: 1500

Cumulative Infections by Week 52 Among Patients with SLE: A Summary of Data from Placebo-Controlled Belimumab Studies
Abstract Number: 1501

Lupus Low Disease Activity State (LLDAS) Achievement with Deucravacitinib, an Oral, Selective, Allosteric Tyrosine Kinase 2 Inhibitor, in a Phase 2 Trial in SLE
Abstract Number: 1502

Introduction of Belimumab Within Five Years of the Onset of Systemic Lupus Erythematosus (SLE) Contributes to the Better Therapeutic Response; A Multi-center Retrospective Cohort Study
Abstract Number: 1503

Disease Course and Complement as Predictors of Response to Standard of Care Plus Placebo in Patients with SLE: A Post Hoc Analysis of Dapirolizumab Pegol and Epratuzumab Clinical Trial Data
Abstract Number: 1504

Characteristics and Prior Treatment Journey of Systemic Lupus Erythematosus (SLE) Patients Who Were Prescribed Anifrolumab — Observations from the American Rheumatology Network (ARN) in the U.S
Abstract Number: 1505

Long-term Safety and Efficacy of Voclosporin in Black Patients with Lupus Nephritis: Results from the AURORA 1 and AURORA 2 Studies
Abstract Number: 1506

Prescribing Patterns in Lupus Nephritis: Analyzing Time from Proteinuria to Prescription of ACE/ARB
Abstract Number: 1507

Pharmacodynamic Changes in SLE Relevant Gene Expression Induced by Deucravacitinib in Patients Enrolled in the Phase 2 PAISLEY Trial
Abstract Number: 1508

Predicting in Virtual Patients the Efficacy of an Anti IFNa Mab in Cutaneous Lupus Erythematosus

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].